This clinical trial is focused on patients with end-stage kidney disease who are undergoing hemodialysis, a treatment that helps clean the blood when the kidneys are not working well. These patients often use a central venous catheter (CVC) as a way to access their blood for dialysis. The study is investigating the use of prophylactic antibiotic treatment to prevent infections, specifically blood poisoning, which is a serious condition that can occur in these patients.

The trial will test two antibiotics: amoxicillin/clavulanic acid and clindamycin. Amoxicillin/clavulanic acid is the primary treatment, but clindamycin will be used for those who cannot tolerate beta-lactam antibiotics, a common type of antibiotic. The purpose of the study is to see if taking these antibiotics can reduce the risk of infections during the first six months after starting hemodialysis with a CVC.

Participants in the study will be randomly assigned to receive either the antibiotic treatment or a placebo. The study will last for six months, during which time the health of the participants will be monitored to see if the antibiotics help prevent infections. The goal is to find out if this approach can help reduce hospitalizations due to infections in patients with end-stage kidney disease who are receiving hemodialysis.